X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
OLT1177 (dapansutrile) is an oral NLRP3 Inhibitor, which is being evaluated for the treatment of patients with early parkinson’s disease.
Lead Product(s): Dapansutrile
Therapeutic Area: Neurology Product Name: OLT1177
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
OLT1177 (dapansutrile) is an NLRP3 inhibitor which is being investigated in combination with pembrolizumab (Keytruda®) in patients with PD-1 refractory advanced melanoma.
Lead Product(s): Dapansutrile,Pembrolizumab
Therapeutic Area: Oncology Product Name: OLT1177
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2023
Details:
The Michael J. Fox Foundation for Parkinson’s Research has awarded a grant from their Therapeutics Pipeline Program to support preclinical research evaluating Olatec Therapeutics’ lead compound, OLT1177 (dapansutrile), an investigational small molecule, in PD.
Lead Product(s): Dapansutrile
Therapeutic Area: Neurology Product Name: OLT1177
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: The Michael J. Fox Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding March 10, 2023
Details:
The net proceeds will be used to advance OLT1177 (dapansutrile) into later stage clinical development. Dapansutrile is an investigational small molecule, that specifically binds to and blocks NLRP3, the sensor molecule integral in the formation of the NLRP3 inflammasome.
Lead Product(s): Dapansutrile
Therapeutic Area: Rheumatology Product Name: OLT1177
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sanders Morris Harris
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing February 23, 2023
Details:
Results suggest a potential therapeutic benefit for dapansutrile in patients with neuroinflammatory diseases, e.g., Alzheimer’s Disease. Preclinical results encourage clinical research with dapansutrile in Alzheimer’s Disease to investigate therapeutic effect in humans.
Lead Product(s): Dapansutrile
Therapeutic Area: Neurology Product Name: OLT1177
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 29, 2020
Details:
The trial will evaluate the safety and efficacy of dapansutrile in approximately 80 ambulatory patients from diverse demographics, randomized 1:1 (dapansutrile:placebo) and treated for 14 days.
Lead Product(s): Dapansutrile
Therapeutic Area: Infections and Infectious Diseases Product Name: OLT1177
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
